



Stirring the Pot With Estrogens

Estradiol Acutely Suppresses Inhibition in the Hippocampus Through a Sex-Specific Endocannabinoid and mGluR-Dependent Mechanism.

Huang GZ, Woolley CS. *Neuron* 2012;74:801–808.

The steroid 17 β -estradiol (E2) is well known to influence hippocampal functions such as memory, affective behaviors, and epilepsy. There is growing awareness that in addition to responding to ovarian E2, the hippocampus of both males and females synthesizes E2 as a neurosteroid that could acutely modulate synaptic function. Previous work on acute E2 actions in the hippocampus has focused on excitatory synapses. Here, we show that E2 rapidly suppresses inhibitory synaptic transmission in hippocampal CA1. E2 acts through the α form of the estrogen receptor to stimulate postsynaptic mGluR1-dependent mobilization of the endocannabinoid anandamide, which retrogradely suppresses GABA release from CB1 receptor-containing inhibitory presynaptic boutons. Remarkably, this effect of E2 is sex specific, occurring in females but not in males. Acute E2 modulation of endocannabinoid tone and consequent suppression of inhibition provide a mechanism by which neurosteroid E2 could modulate hippocampus-dependent behaviors in a sex-specific manner.

Commentary

Estrogens, GABA_A receptors (GABA_AR), metabotropic glutamate receptors (mGluRs), and endogenous cannabinoids, such as anandamide, are well known neuromodulators with sex-specific effects on brain development and function. Huang and Woolley link these four signaling pathways by proposing a new feedback loop through which 17 β -estradiol triggers an mGluR1-mediated increase in the retrograde release of anandamide, which activates cannabinoid receptors 1 (CB1R) and suppresses GABA_AR-IPSCs. The 17 β -estradiol regulation of GABA_AR-IPSCs appears to involve coupling of estrogen receptor α (ER α) with mGluR1 and occurs in ovariectomized female, but not in castrated or gonadally intact male rats. The study involves postnatal day (PN) 47 to 57 rats, which are considered as late pubertal or early adults. These findings highlight once again the complex and sex-specific interactions among signaling systems that affect hippocampal activity. The current study was conducted in seizure-naïve rats, with unclear implications for the hippocampus of a rat exposed to seizures.

17 β -estradiol is well known for its sex-specific, cell-type, age, and activity-dependent effects (1-4). Indeed, the authors here demonstrate the predilection for 17 β -estradiol to reduce GABA_AR-IPSCs in ovariectomized females but not in gonadally intact or castrated males. The use of nM concentrations of 17 β -estradiol was intended to parallel the high local concentrations of the neurosteroid, which range between 5 to 10 nM in the adult male hippocampus (5). It is, however, surprising

that the ER β -preferring agonist diarylpropionitrile, at doses that can activate both ER α and ER β (500 nM), was completely inactive (6). ER/mGluR coupling occurs in hypothalamic neurons and glial cells (3), does not require presynaptic glutamate release (1), and may involve ER α or ER β . The type of mGluR involved (mGluR1/5 or mGluR2/3) determines the downstream effects (3), which can be sex-specific (1). For instance, in early postnatal hippocampal cultures, ER α /mGluR1 may trigger phosphorylation of cAMP-responsive element binding protein (pCREB), whereas ER(α or β)/mGluR2/3 coupling may reduce pCREB (1).

The authors hypothesize that 17 β -estradiol may regulate presynaptic GABA release, although potential effects on postsynaptic GABA_ARs are also worth investigating, given the lasting suppression of GABA_AR-IPSC. However, the search for a presynaptic messenger led to fruitful links to endocannabinoid signaling, since the 17 β -estradiol effects seemed to be mediated by retrograde release of anandamide. Although the sex-specific mechanisms are not explored here, these are likely to be tissue-specific, since potentiation of anandamide-induced vasorelaxation by 17 β -estradiol occurs in mesenteric arteries of male but not of female rats (7).

CB1R-mediated regulation of GABA_AR signaling, via 2-arachidonoylglycerol (2-AG) and/or anandamide, has been reported in the hippocampus of rodents of either undetermined sex (8-10) or of young male rats (11). Interestingly, here, only anandamide mediates the 17 β -estradiol-induced suppression of GABA_AR-IPSCs. Inhibition of fatty acid amide hydroxylase (FAAH), which catabolizes anandamide, by URB 597 masked the 17 β -estradiol effect on GABA_AR-IPSCs, whereas blockade of 2-AG breakdown had no such effect. This is not necessarily surprising considering that 17 β -estradiol may increase anan-



damide synthesis or inhibit its catabolizing enzyme, FAAH (12, 13). The inactivity of 17 β -estradiol, when the FAAH inhibitor URB 597 is applied, could then be due to the occupancy of its target by URB 597, yet this possibility is not further investigated. In further support, the plasma levels of anandamide correlate nicely with the levels of estrogen during the menstrual cycle in women (13). It is tempting to cite here the clinical studies that find increased frequency of certain types of seizures during menstrual cycle periods with increased estrogen/progesterone serum level ratios (14) and question whether this anandamide-induced decrease in GABA_AR signaling might be one of the mechanisms involved in the observed increased seizure frequency. But then, why isn't the frequency of other focal-onset seizure types increased as well.

Could this 17 β -estradiol/anandamide signaling-induced disinhibition of the hippocampus reveal a new mechanism underlying the pro-convulsant actions of high 17 β -estradiol levels? In support of this possibility, FAAH(-/-) mice show increased seizure severity in the bicuculline and kainic acid models, which was further accentuated by concomitant anandamide administration, without any reported sex differences (15). In contrast, in PN21-24 old rats of undetermined sex, FAAH inhibition had antiseizure effects in the kainic acid model (16). The rest of the existing studies on anandamide effect on seizures have been done in males and are difficult to compare with the authors' findings. Rather, the existing studies tend to suggest dose and model-specific effects, as well as the involvement of additional signaling pathways (17-20).

It is also unclear how significant this pathway may be in disinhibiting an epileptic hippocampus, where (a) GABA may be depolarizing rather than hyperpolarizing in certain hippocampal regions (21), (b) endocannabinoids may also reduce the excitatory postsynaptic currents (22), and (c) the circuitry of connections and the involved signaling pathways may be undergoing drastic changes from normal controls.

Overall, this is an elegant study, which incrementally unravels an exciting sequence of events leading to the sex-specific regulation of GABA_AR IPSCs in the hippocampus by 17 β -estradiol and endocannabinoids. Further experiments will be needed to clarify the relevance of the current findings not only to epilepsy but also to normal cognitive processes, drug addiction, or other neurological disorders involving the hippocampal structures and endocannabinoid signaling. The relevance of these *in vitro* observations to an intact, healthy or diseased organism that undergoes continuous changes through time, remains unclear. Deciphering these issues is always a challenge in any research that investigates activity-related functions.

by Aristeia S. Galanopoulou, MD PhD

References

1. Boulware MI, Weick JP, Becklund BR, Kuo SP, Groth RD, Mermelstein PG. Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. *J Neurosci* 2005; 25: 5066-78.
2. Galanopoulou AS. Sexually dimorphic expression of KCC2 and GABA function. *Epilepsy Res* 2008; 80: 99-113.
3. Mermelstein PG. Membrane-localised oestrogen receptor alpha and beta influence neuronal activity through activation of metabotropic glutamate receptors. *J Neuroendocrinol* 2009; 21: 257-62.
4. Wright CL, Schwarz JS, Dean SL, McCarthy MM. Cellular mechanisms of estradiol-mediated sexual differentiation of the brain. *Trends Endocrinol Metab* 2010; 21: 553-61.
5. Hojo Y, Higo S, Ishii H, Ooishi Y, Mukai H, Murakami G, Kominami T, Kimoto T, Honma S, Poirier D, Kawato S. Comparison between hippocampus-synthesized and circulation-derived sex steroids in the hippocampus. *Endocrinology* 2009; 150: 5106-12.
6. Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA, Katzenellenbogen BS. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. *Mol Cell Endocrinol* 2003; 206: 13-22.
7. Ho WS. Modulation by 17beta-estradiol of anandamide vasorelaxation in normotensive and hypertensive rats: A role for TRPV1 but not fatty acid amide hydrolase. *Eur J Pharmacol* 2013; 701: 49-56.
8. Castillo PE, Younts TJ, Chavez AE, Hashimoto Y. Endocannabinoid signaling and synaptic function. *Neuron* 2012; 76: 70-81.
9. Chevalyere V, Castillo PE. Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. *Neuron* 2003; 38: 461-72.
10. Pan B, Wang W, Long JZ, Sun D, Hillard CJ, Cravatt BF, Liu QS. Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling. *J Pharmacol Exp Ther* 2009; 331: 591-7.
11. Kim J, Alger BE. Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. *Nat Neurosci* 2004; 7: 697-8.
12. Maccarrone M, Bari M, Battista N, Finazzi-Agro A. Estrogen stimulates arachidonylethanolamide release from human endothelial cells and platelet activation. *Blood* 2002; 100: 4040-8.
13. Karasu T, Marczylo TH, Maccarrone M, Konje JC. The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility. *Hum Reprod Update* 2011; 17: 347-61.
14. Herzog AG, Fowler KM, Sperling MR, Liporace JD, Kalayjian LA, Heck CN, Krauss GL, Dworetzky BA, Pennell PB, Progesterone Trial Study G. Variation of seizure frequency with ovulatory status of menstrual cycles. *Epilepsia* 2011; 52: 1843-8.
15. Clement AB, Hawkins EG, Lichtman AH, Cravatt BF. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. *J Neurosci* 2003; 23: 3916-23.
16. Karanian DA, Karim SL, Wood JT, Williams JS, Lin S, Makriyannis A, Bahr BA. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. *J Pharmacol Exp Ther* 2007; 322: 1059-66.
17. Vilela LR, Medeiros DC, Rezende GH, de Oliveira AC, Moraes MF, Moreira FA. Effects of cannabinoids and endocannabinoid hydrolysis inhibition on pentylenetetrazole-induced seizure and electroencephalographic activity in rats. *Epilepsy Res* 2013.
18. Citraro R, Russo E, Scicchitano F, van Rijn CM, Cosco D, Avagliano C, Russo R, D'Agostino G, Petrosino S, Guida F, Gatta L, van Luijckelaer G, Maione S, Di Marzo V, Calignano A, De Sarro G. Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-alpha receptor activation in a genetic model of absence epilepsy. *Neuropharmacology* 2013; 69: 115-26.



19. Manna SS Umathe SN. Involvement of transient receptor potential vanilloid type 1 channels in the pro-convulsant effect of anandamide in pentylenetetrazole-induced seizures. *Epilepsy Res* 2012; 100: 113-24.
20. Wendt H, Soerensen J, Wotjak CT, Potschka H. Targeting the endocannabinoid system in the amygdala kindling model of temporal lobe epilepsy in mice. *Epilepsia* 2011; 52: e62-5.
21. Cohen I, Navarro V, Clemenceau S, Baulac M, Miles R. On the origin of interictal activity in human temporal lobe epilepsy in vitro. *Science* 2002; 298: 1418-21.
22. Bhaskaran MD Smith BN. Cannabinoid-mediated inhibition of recurrent excitatory circuitry in the dentate gyrus in a mouse model of temporal lobe epilepsy. *PLoS One* 2010; 5: e10683.



American Epilepsy Society

Epilepsy Currents Journal

Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.

Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Other relationships

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



American Epilepsy Society

Epilepsy Currents Journal

Disclosure of Potential Conflicts of Interest

Section #1 Identifying Information

1. Today's Date: 5/21/13
2. First Name Aristeia Last Name Galanopoulou Degree MD PhD
3. Are you the Main Assigned Author? Yes No
If no, enter your name as co-author:
4. Manuscript/Article Title: Stirring the pot with estrgens
5. Journal Issue you are submitting for: Vol 13, No 3 (May/June)

Section #2 The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship just add rows to this table.

Type	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**
1. Grant	<input checked="" type="checkbox"/>				
2. Consulting fee or honorarium	<input checked="" type="checkbox"/>				
3. Support for travel to meetings for the study or other purposes	<input checked="" type="checkbox"/>				
4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like	<input checked="" type="checkbox"/>				
5. Payment for writing or reviewing the manuscript	<input checked="" type="checkbox"/>				
6. Provision of writing assistance, medicines, equipment, or administrative support.	<input checked="" type="checkbox"/>				
7. Other	<input checked="" type="checkbox"/>				

* This means money that your institution received for your efforts on this study.

** Use this section to provide any needed explanation.

Section #3 Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

Type of relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**
1. Board membership	<input checked="" type="checkbox"/>				
2. Consultancy	<input checked="" type="checkbox"/>				
3. Employment	<input checked="" type="checkbox"/>				
4. Expert testimony	<input checked="" type="checkbox"/>				
5. Grants/grants pending	<input type="checkbox"/>		Yes	CURE, NINDS, Autism Speaks	Salary support and supplies
6. Payment for lectures including service on speakers bureaus	<input type="checkbox"/>	Yes		Novartis / Sui generis	Honorarium for participating as a speaker in a conference
7. Payment for manuscript preparation.	<input checked="" type="checkbox"/>				
8. Patents (planned, pending or issued)	<input checked="" type="checkbox"/>				
9. Royalties	<input type="checkbox"/>	Yes			Morgan & Claypool, John Libbey Eurotext, royalties for publications (Books)
10. Payment for development of educational presentations	<input checked="" type="checkbox"/>				
11. Stock/stock options	<input checked="" type="checkbox"/>				
12. Travel/accommodations/meeting expenses unrelated to activities listed.**	<input type="checkbox"/>	Yes		AES, ILAE, CURE, Autism Speaks, Epilepsy Therapy Project, NINDS, University of Davis CA	Travel expenses for participating in conference
13. Other (err on the side of full disclosure)	<input type="checkbox"/>				

* This means money that your institution received for your efforts.

** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section #4 Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- No other relationships/conditions/circumstances that present a potential conflict of interest.
 Yes, the following relationships/conditions/circumstances are present:

Thank you for your assistance.
Epilepsy Currents Editorial Board